After working through the night, the Republican majority in the U.S. House Energy and Commerce Committee overrode the Democratic members Thursday to pass the committee print of recommendations intended to repeal and replace parts of the Affordable Care Act (ACA). Read More
Vivus Inc., of Campbell, Calif., reported net income for the fourth quarter and full year of $56.6 million and $23.3 million, respectively, compared to a net loss of $12.2 million and $93.1 million, respectively, in 2015. Total revenue for the quarter was $81.8 million and for the full year was $124.3 million. Read More
TG Therapeutics Inc., of New York, said it priced a public offering of about 5.1 million shares at $9.75 per share, with expected gross proceeds of $50 million. The company also granted underwriters a 30-day option to purchase up to an additional 769,230 shares of common stock. Read More
Like their biopharmaceutical colleagues, publicly listed medical technology companies have roared out of the gate this year as investors flood back into health care. Companies have benefited from record-breaking market highs being driven by a increased optimism that the U.S. economy is poised to enjoy better times ahead. Read More
TAIPEI, Taiwan – During the two days of talks, roundtables and panel discussions at Biologics World Taiwan 2017, much of the attention speakers devoted to Taiwan focused on what the country is not getting right, from government support and policies, to competing with regional rivals. Read More
Engineered blood cells were able to alleviate and prevent symptoms of type I diabetes (T1D) and multiple sclerosis (MS), two of the more common autoimmune diseases, by inducing immune tolerance to antigens. Read More
Drugmakers looking to the FDA's 505(b)(2) pathway for shorter approval times may want to think again. A new report says the filings, generally expected to streamline development and review, instead took an average of about five months longer than those for new molecular entities (NMEs) in recent years. Read More
Beyondspring Inc. priced its IPO of 174,286 shares at $20 each and sold about 2.5 million shares at the same price in a private placement, hauling down about $54.3 million, which "probably for some companies is not that much," CEO Lan Huang told BioWorld Today. "But it can really help us to run our current defined clinical programs," since the New York-headquartered company bases its clinical operations in China. Shares (NASDAQ:BYSI) closed Thursday at $16.80, down 16 percent. Read More
Opthea Ltd., of Melbourne, Australia, said it completed a type C meeting with the FDA aimed at obtaining regulatory guidance on the clinical development program and proposed phase IIb trial testing OPT-302, a VEGF-C/D trap therapy, in wet age-related macular degeneration. Read More
